The role of astrocytes in multiple sclerosis progression

Frontiers in Neurology

Volumn 6, Issue Aug, 2015, Pages

  Correale, Jorge ^a   Farez, Mauricio F ^a  

^a FLENI   (Argentina)

Author keywords

Astrocytes; Axon; Glial scar; Microglia; Mitochondria; Multiple sclerosis; Multiple sclerosis progression; Myelin

Indexed keywords

B CELL ACTIVATING FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; NITRIC OXIDE; PURINERGIC P2Y RECEPTOR;

AGING; ASTROCYTE; BRAIN MITOCHONDRION; CELL ACTIVATION; CELL FUNCTION; CYTOKINE RELEASE; DISEASE COURSE; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NERVE CELL DIFFERENTIATION; NERVE FIBER REGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REMYELINIZATION; REVIEW;

EID: 84940871696     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00180     Document Type: Review

References (140)

1. McFarland HF, Martin R.Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol (2007) 8(9):913-9. doi: 10.1038/ni1507.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology (1996) 46(4):907-11. doi:10.1212/WNL.46.4.907.
3. Cohen JA, Rudick RA. Multiple Sclerosis Therapeutics. New York, NY: Cambridge UniveristyPress (2011). 752 p.
4. Mahad DH, Trapp BD, Lassman H. Progressive multiple sclerosis 1. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol (2015) 14(2):183-93. doi:10.1016/S1474-4422(14)70256-X.
5. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 338(5):278-85. doi:10.1056/NEJM199801293380502.
6. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the new forming lesions. Ann Neurol (2004) 55(4):458-68. doi:10.1002/ana.20016.
7. Petterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neuritis, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol (2001) 50(3):389-400. doi:10.1002/ana.1123.
8. Trapp BD, Nave KA. Multiple sclerosis: an immune and neurodegenerative disorder? Annu Rev Neurosci (2008) 31:247-69. doi:10.1146/annurev.neuro.30.051606.094313.
9. Bø L. The histopathology of grey matter demyelination in multiple sclerosis. Acta Neurol Scand (2009) 189:51-7. doi:10.1111/j.1600-0404.2009.01216.x.
10. Mayo L, Quintana FJ, Weiner HL. The innate immune system in demyelinating disease. Immunol Rev (2012) 248(1):170-87. doi:10.1111/j.1600-0404.2009.01216.x.
11. Rindfleish E. Histologisches detail zur grauen degeneration von gehirn und rückermark. Arch Pathol Anat Physiol Klin Med (1863) 26:474-83. doi:10.1007/BF01878008.
12. Müller E. Pathologishes anatomie and pathogenese. In: Fisher G, editor. Die Multiple Skleroze des Gehirms und Rückenmarks. Jena: Verlag (1904). p. 300-44.
13. Anton G, Wohlwill F. Multiple nicht eitirge encephalomyelitis und multiple skleroze. Z Ges Neurol Psych (1912) 12:31-99. doi:10.1007/BF02866371.
14. Brosnan CF, Raine CS. The astrocyte in multiple sclerosis revisited. Glia (2013) 61(4):453-65. doi:10.1002/glia.22443.
15. He F, Sun YE. Glial cells more tan support cells? Int J Biochem Cell Biol (2007) 39(4):661-5. doi:10.1016/j.biocel.2006.10.022.
16. Butt AM, Duncan A, Berry M. Astrocyte associations with nodes of ranvier: ultrastructural analysis of HRP-filled astrocytes in the mouse optic nerve. J Neurocytol (1994) 23(8):486-99. doi:10.1007/BF01184072.
17. Chao TI, Rickman M, Wolff JR. The synapse-astrocyte boundary: anatomical basis for an integrative role of glia in synaptic transmission. In: Volterra A, Magistretti P, Haydon P, editors. Tripartate Synapses: Synaptic Transmission with Glia. New York, NY: Oxford University Press (2002). p. 3-23.
18. Reinchenbach A, Wolburg H. Astrocytes and ependymal glia. In: Kettenmann H, Ranson BR, editors. Neuroglia. New York, NY: Oxford University Press (2013). p. 35-49.
19. Lundgaard I, Osório MJ, Krees BT, Sangaard S, Nedergaard M. White matter astrocytes in health and disease. Neuroscience (2014) 276:161-73. doi:10.1016/j.neuroscience.2013.10.050.
20. Nair A, Frederick TJ, Miller D. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci (2008) 65(17):2702-20. doi:10.1007/s00018-008-8059-5.
21. Tsai HH, Li H, Fuentealba LC, Molofsky AV, Taveira-Marques R, Zhuang H, et al. Regional astrocyte allocation regulates CNS synaptogenesis and repair. Science (2012) 337(6092):358-62. doi:10.1126/science.1222381.
22. Molofsky AV, Krencik R, Ulian EM, Tsai HH, Denereen B, Richardson WD, et al. Astrocytes and disease: a neurodevelopment perspective. Genes Dev (2012) 26(9):891-907. doi:10.1101/gad.188326.112.
23. Wang DD, Bordey A. The astrcoyte odyssey. Prog Neurobiol (2008) 86(4):342-67. doi:10.1016/j.pneurobio.2008.09.015.
24. Emsley JG, Macklis JD. Astroglial heterogeneity closely reflects the neuronal-defined anatomy of the adult murine CNS. Neuron Glia Biol (2006) 2(3):175-86. doi:10.1017/S1740925X06000202.
25. Goldan JE. Astrocyte development. In: Kettenmann H, Ranson BR, editors. Neuroglia. New York, NY: Oxford Univeristy Press (2013). p. 137-47.
26. Hatada I, Namihira M, Morita S, Kimura M, Horii T, Nakashima K, et al. Astrocyte-specific genes are geenrally demethylated in neural precursor cells prior to astrocytic differentiation. PLoS One (2008) 3:3189. doi:10.1371/journal.pone.0003189.
27. Fan G, Martinowich K, Chin MH, He F, Fouse SD, Hutnick L, et al. DNA methylation controls the timing of astroglio-genesis through regulation of JAK-STAT signaling. Development (2005) 132(15):3345-56. doi:10.1242/dev.01912.
28. Sun D, Jakobs TC. Structural remodeling of astrocytes in the injured CNS. Neuroscientist (2012) 18(6):567-88. doi:10.1177/1073858411423441.
29. Seifert G, Schilling K. Steinhäuser. Astrocyte dysfunction in neurological disorders: a molecular perspective. Nat Rev Neurosci (2006) 7(3):194-206. doi:10.1038/nrn1870.
30. Ulian EM, Sapperstein SK, Christopherson KS, Barres A. Control of synapses number by glia. Science (2001) 291(5504):657-61. doi:10.1126/science.291.5504.657.
31. MacVicar BA, Feighan D, Brown A, Ramson B. Intrinsic optical signals in the rat optic nerve role for K+ uptake via NKCC1 and swelling of astrocytes. Glia (2002) 37(2):114-23. doi:10.1002/glia.10023.
32. Göritz C, Mauch DH, Nägler K, Pfrieger FW. Role of glia-derived cholesterol in synaptogenesis: new revelations in the synapse-glia affair. J Physiol Paris (2002) 96(3-4):257-63. doi:10.1016/S0928-4257(02)00014-1.
33. Abbot NJ, Ronnback L, Hansson E. Astrocye-endothelial interactions at the blood brain barrier. Nat Rev Neurosci (2006) 7(1):41-53. doi:10.1038/nrn1824.
34. Kang J, Jiang L, Goldman SA, Nedergaard M. Astrocye-mediated potentiation of inhibitory synaptic transmission. Nat Neurosci (1998) 1(8):683-92. doi:10.1038/3684.
35. Ludwin SK, Raine CS. The neuropathology of MS. In Raine CS, McFarland HF, Hohlfeld R, editors. Multiple Sclerosis: A Comprehensive Text. New York, NY: Sanders/Elsevier (2008). p. 151-77.
36. Argaw AT, Zang Y, Snyder BJ, Zhao ML, Kopp N, Lee SC, et al. IL-1beta regulates blood-brain-barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol (2006) 177(8):5574-84. doi:10.4049/jimmunol.177.8.5574.
37. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain-barrier breakdown. Proc Natl Acad Sci USA (2009) 106(6):1977-82. doi:10.1073/pnas.0808698106.
38. Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, Marianin JN, et al. Astrocyte derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest (2012) 122(7):2454-68. doi:10.1172/JCI60842.
39. Williams A, Piaton G, Lubetzki C. Astrocytes-friends or foes in multiple sclerosis? Glia (2007) 55(13):1300-12. doi:10.1002/glia.20546.
40. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol (2012) 4(3):a006049. doi:10.1101/cshperspect.a006049.
41. Miyake Y, Yamasaki S. Sensing necrotic cells. Adv Exp Med Biol (2012) 738:144-52. doi:10.1007/978-1-4614-1680-7_9.
42. Farina C, Aloisi F, Mainl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol (2007) 28(3):138-45. doi:10.1016/j.it.2007.01.005.
43. Gimenez MAT, SIM JE, Rusell JH. TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation. J Neuroimmunol (2004) 151(1-2):116-25. doi:10.1016/j.jneuroim.2004.02.012.
44. Sobel RA, Mitchell ME, Fondren G. Intracellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol (1990) 136(6):1309-16.
45. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler (2003) 9(6):540-9. doi:10.1191/1352458503ms965oa.
46. Didier N, Romero JA, Creminon C, Wijkhuisen A, Grassi J, Mabondzo A. Secretion of interleukin-1 beta by astrocytes mediates endothelin-1 and tumor necrosis factor-alpha effects on human brain microvascualr endothelial cell permeability. J Neurochem (2003) 86(1):246-54. doi:10.1046/j.1471-4159.2003.01829.x.
47. Dong Y, Benveniste EN. Immune functions of astrocytes. Glia (2001) 36(2):180-90. doi:10.1002/glia.1107.
48. Calderon TM, Eugenin EA, Lopez L, Kumar SS, Hesselgesser J, Raine CS, et al. A role of CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol (2006) 177(1-2):27-39. doi:10.1016/j.jneuroim.2006.05.003.
49. Salmaggi A, Gelati M, Dufour A, Corsini E, Pagano S, Baccalini R, et al. Expression and modulation of IFN-gamma inducible chemokines (IP-10, Mig, and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis. J Interferon Cytokine Res (2002) 22(6):631-40. doi:10.1089/10799900260100114.
50. Karpus WJ, Ransohoff RM. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J Immunol (1998) 161(6):2667-71.
51. Milijkovic D, Moncilovic M, Stojanovic I, Stosio-Grujicic S, Ramiz Z, Mostarica-Stojovic M. Astrocytes stimulate interleukin-17 and interferon-gamma production in vitro. J Neurosci Res (2007) 85(16):3598-606. doi:10.1002/jnr.21453.
52. Liu JQ, Carl JW Jr, Joshi PS, RayCahudhury A, Pu XA, Shi FD, et al. CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis. J Immunol (2007) 178(10):6227-35. doi:10.4049/jimmunol.178.10.6227.
53. Zhou Y, Sonobe Y, Akahori T, Jin S, Kawanokuchi J, Noda M, et al. IL-9 promotes Th17 cell migration into the central nervoous system via CC chemokine ligand-20 produced by astrocytes. J Immunol (2011) 186(7):4415-21. doi:10.4049/jimmunol.1003307.
54. Saikali P, Antel JP, Pittet CL, Newcombe J, Arbour N. Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis. J Immunol (2010) 185(10):5693-703. doi:10.4049/jimmunol.1002188.
55. Bechmann I, Steiner B, Gimsa U, Mor G, Wolf S, Beyer M, et al. Astrocyte-induced T cell elimination is CD95 ligand dependent. J Neuroimmunol (2002) 132(1-2):60-5. doi:10.1016/S0165-5728(02)00311-9.
56. Zhu C, Anderson AC, Kuchroo VK. Tim-3 and its regulatory role in immune responses. Curr Top Microbiol Immunol (2011) 350:1-15. doi:10.1007/82_2010_84.
57. Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, et al. Baff is produced by astrocytes and upregualted in multiple sclerosis lesions and primary centrol nervous system lymphoma. J Exp Med (2005) 201(2):195-200. doi:10.1084/jem.20041674.
58. Toft-Hansen H, Füchtbauer L, Owens T. Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease. Glia (2011) 59(1):166-76. doi:10.1002/glia.21088.
59. DeWitt DA, Perry G, Cohen M, Doller C, Silver J. Astrocytes regulate microglial phagocytosis of senile plaque core of Alzheimer's disease. Exp Neurol (1998) 149(2):329-40. doi:10.1006/exnr.1997.6738.
60. Zeinstra E, Wilczak N, Streefland C, Keyser JD. Astrocytes in chronic active multiple sclerosis plaques express MHC Class II molecules. Neuroreport (2000) 11(1):89-91. doi:10.1097/00001756-200001170-00018.
61. Chastain EML, Duncan DS, Rodgers JM, Miller DS. The role of antigen presenting cells in multiple sclerosis. Biochem Biophys Acta (2011) 1812(2):265-74. doi:10.1016/j.bbadis.2010.07.008.
62. Kort JJ, Kawamura K, Fugger L, Weissert R, Forsthuber TG. Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not proteins by astrocytes from HLA-DR2 and HLA-DR4 transgenic mice. J Neuroimmunol (2006) 173(1-2):23-34. doi:10.1016/j.jneuroim.2005.11.014.
63. Mayo L, Trauger SA, Balin M, Nadeu M, Patel B, Alvarez JI, et al. Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat Med (2014) 20(10):1147-56. doi:10.1038/nm.3681.
64. Pannu R, Won JS, Khan M, Singh AK, Singh I. A novel role of lactosylceramida in the regulation of lipopolysaccharide interferon-gamma mediated inducible nitric oxide syntahse gene expression: implications for neuroinflammatory diseases. J Neurosci (2004) 24(26):5942-54. doi:10.1523/JNEUROSCI. 1271-04.2004.
65. Bal-Price A, Brown GC. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci (2001) 21(17):6480-91.
66. Trajkovic V, Stosic-Grujicic S, Samardzic T, Markovic M, Milijovic D, Ramicz Z, et al. Interleukin-17 stimulates inducible nitric oxide synthase activation in rodent astrocytes. J Neuroimmunol (2001) 119(2):183-91. doi:10.1016/S0165-5728(01)00391-5.
67. Hamby ME, Hewet JA, Hewet SJ. TGF-beta 1 potentiates astrocytic nitric oxide production by expanding the population of astrocytes that express NOS-2. Glia (2006) 54(6):566-77. doi:10.1002/glia.20411.
68. Lee SC, Dickson DW, Liu W, Brosnan CF. Induction of nitric oxide synthase activity in human astrocytes by interleukin-1 beta and interferon-gamma. J Neuroimmunol (1993) 46(1-2):19-24. doi:10.1016/0165-5728(93)90229-R.
69. Brosnan CF, Battistini L, Raine CS, Dickson DW, Casadevall A, Lee SC. Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci (1994) 16(3-4):152-61. doi:10.1159/000112102.
70. Liu JS, Zhao ML, Brosnan CF, Lee SC. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol (2001) 158(6):2057-66. doi:10.1016/S0002-9440(10)64677-9.
71. Stojanovic IR, Kostic M, Ljubisavljevic S. The role of glutamate and its recpeors in multiple sclerosis. J Neural Transm (2014) 121(8):945-55. doi:10.1007/s00702-014-1188-0.
72. Kumar P, Kalonia H, Kumar A. Possible GBAERGIC mechanism in the neurorptective effect of gabapentin and lamotirgine against 3-nitropropionic acid induced neurotoxicity. Eur J Pharmacol (2012) 674(2-3):265-74. doi:10.1016/j.ejphar.2011.11.030.
73. Rossi S, Motta C, Studer V, Barbieri F, Butari F, Bergami A, et al. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler (2014) 20(3):304-12. doi:10.1177/1352458513498128.
74. Matute C, Sanchez-Gomez MV, Martinez-Millan L, Miledi R. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci U S A (1997) 94(16):8830-5. doi:10.1073/pnas.94.16.8830.
75. Korn T, Magnus T, Jung S. Autoantigen specific T cells inhibit glutamate uptake in astrocytes by decreasing expression of astrocytic glutamate transporter GLAST: a mechanism mediated by tumor necrosis-alpha. FASEB J (2005) 19(13):1878-80.
76. Rothstein JD, Dykes-Hoberg M, PArdo CA, Bristol LA, Jin L, Kuncl RW, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron (2006) 16(3):675-86. doi:10.1016/S0896-6273(00)80086-0.
77. Ouardouz M, Coderre E, Basak A, Chen A, Zamponi GW, Hameed S, et al. Glutamate receptors on myelinated spinal cord axons. I. GluR6 kainate receptors. Ann Neurol (2009) 65(2):151-9. doi:10.1002/ana.21533.
78. Ouardouz M, Coderre E, Zamponi GW, Hameed S, Yin X, Trapp BD, et al. Glutamate receptors on myelinated spinal cord axons. II. AMPA and GluR5 receptors. Ann Neurol (2009) 65(2):160-6. doi:10.1002/ana.21539.
79. Nicholls DG. Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. Curr Mol Med (2004) 4(2):149-77. doi:10.2174/1566524043479239.
80. Norenberg MD, Rao KV. The mitochondrial permeability transition in neurological disease. Neurochem Int (2007) 50(7-8):983-97. doi:10.1016/j.neuint.2007.02.008.
81. Salter MG, Fern R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature (2005) 438(7071):1167-71. doi:10.1038/nature04301.
82. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med (2000) 6(1):67-70. doi:10.1038/71555.
83. Franke H, Verkhratsky A, Burnstock G, Illes P. Pathophysiology of astroglial purinergic signaling. Purinergic Signal (2012) 8(3):629-57. doi:10.1007/s11302-012-9300-0.
84. Narcisse L, Scemes E, Zhao Y, Lee SC, Brosnan CF. The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes. Glia (2005) 49(2):245-58. doi:10.1002/glia.20110.
85. Matute C, Torre I, Pérez-Cerdá F, Pérez-Samartín A, Alberdi E, Etxebarria E, et al. P2X(7) recpetor blockade prevents ATP excitotoxicity in oligodendrocyes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci (2007) 27(35):9525-37. doi:10.1523/JNEUROSCI. 0579-07.2007.
86. Chen ZJ, Negra M, Levine A, Ughrin Y, Levine JM. Oligodendrocyte precursor cells: reactive cells that inhibit axon growth and regeneration. J Neurocytol (2002) 31(6-7):481-95. doi:10.1023/A 1025791614468.
87. Bundesen LQ, Scheel TA, Bregman BS, Kromer LF. EPhrin-B2 and EPhB2 regulation of astrocyte-meningeal fibroblast interactions in response to spinal cord lesions in adult rats. J Neurosci (2003) 23(21):7789-800.
88. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty one years (1969-2000). Neurochem Res (2000) 25(9-10):1439-51. doi:10.1023/A: 1007677003387.
89. Robel S, Berninger B, Gôtz M. The stem cell potential of glia: lessons from reactive gliosis. Nat Rev Neurosci (2013) 12(2):88-104. doi:10.1038/nrn2978.
90. Balasingam V, Tejada-Borges T, Wright E, Bouckova R, Yong VW. Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines. J Neurosci (1994) 14(2):846-56.
91. Sriram K, Benkovic SA, Hebert MA, Miller DB, O'Callaghan JP. Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo? J Biol Chem (2004) 279(19):19936-47.
92. Robel S, Mori T, Zoubaa S, Schlegel J, Sirko S, Faissner A, et al. Conditional deletion of beta-1 integrin in astroglia causes partial reactive gliosis. Glia (2009) 57(15):1630-47. doi:10.1002/glia.20876.
93. Kanemaru K, Kubota J, Sekiya H, Hirose K, Okubo Y, Iino M. Calcium-dependent N-cadherin up-regulation mediates reactive astrogliosis and neuroprotection after brain injury. Proc Natl Acad Sci U S A (2013) 110(28):11612-7. doi:10.1073/pnas.1300378110.
94. Erschbamer M, Pernold K, Olson L. Inhibiting epidermal growth factor receptor improves structural, locomotor, sensory, and bladder recovery from experimental spinal cord injury. J Neurosci (2007) 27(24):6428-35. doi:10.1523/JNEUROSCI. 1037-07.2007.
95. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev (1998) 50(3):413-92.
96. Robel S, Bardehle S, Lepier A, Brakebusch C, Götz M. Genetic deletion of cdc42 reveals a crucial role for astrocyte recruitment to the injury site in vitro and in vivo. J Neurosci (2011) 31(35):12471-82. doi:10.1523/JNEUROSCI. 2696-11.2011.
97. Beck H, Plate KH. Angiogenesis after cerebral ischemia. Acta Neuropathol (2009) 117(5):481-96. doi:10.1007/s00401-009-0483-6.
98. Zhang ZG, Chopp M. Neurorestorative therapies for stroke; underlying mechanisms and translation to the clinic. Lancet Neurol (2009) 8(5):491-500. doi:10.1016/S1474-4422(09)70061-4.
99. Nakazawa T, Takeda M, Lewis GP, Cho KS, Jiao J, Wilhelmsson U, et al. Attenuated glial recations and photoreceptor degeneration after retinal detachment in mice deficient of glial fibrillary acidic protein and vimentin. Invest Ophthalmol Vis Sci (2007) 48(6):2760-8. doi:10.1167/iovs.06-1398.
100. Herrmann JE, Imura T, Song B, Qi J, Ao Y, Nguyen TK, et al. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci (2008) 28(28):7231-43. doi:10.1523/JNEUROSCI. 1709-08.2008.
101. Okada S, Nakamura M, Katoh H, Miyao T, Shimazaki T, Ishii K, et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med (2006) 12(7):829-34. doi:10.1038/nm1425.
102. Neary JT, Kang Y. Signaling from P2 nucleotide receptors to protein kinase cascades induced by CNS injury: implications for reactive gliosis and neurodegeneration. Mol Neurobiol (2005) 31(1-3):95-105. doi:10.1385/MN:31:1-3:095.
103. Washburn KB, Neary JT. P2 purinergic receptors signal to STAT3 in astrocytes: Difference in STAT3 responses to P2Y and P2X receptor activation. Neuroscience (2006) 142(2):411-25. doi:10.1016/j.neuroscience.2006.06.034.
104. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci (2004) 5(2):146-56. doi:10.1038/nrn1326.
105. Holley JE, Gveric D, Newcombe J, Cuzner ML, Gutowski NJ. Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol Appl Neurobiol (2003) 29(5):434-44. doi:10.1046/j.1365-2990.2003.00491.x.
106. Goddard DR, Berry M, Butt AM. In vivo actions of fibroblast growth factor-2 and insulin-like growth factor-I on oligodendrocyte development and myelination in the central nervous system. J Neurosci Res (1999) 57(1):74-85. doi:10.1002/(SICI)1097-4547(19990701)57:1<74::AID-JNR8>3.0.CO;2-O.
107. Sherman LS, Struve JN, Rangwala R, Wallingford NM, Tuohy TM, Kuntz CT. Hyaluronate-based extracellular matrix: keeping glia in their place. Glia (2002) 38(2):93-102. doi:10.1002/glia.10053.
108. Soilu-Hanninen M, Laaksonen M, Hanninen A. Hyaluronate receptor (CD44) and integrin alpha4 (CD49d) are upregulated on T cells during MS relapses. J Neuroimmunol (2005) 166(1-2):189-92. doi:10.1016/j.jneuroim.2005.05.008.
109. Back SA, Tuohy TM, Chen H, Wallingford N, Craig A, Struve J, et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med (2005) 11(9):966-72.
110. Johnson-Green PC, Dow KE, Riopelle RJ. Characterization of glycosaminoglycans produced by primary astrocytes in vitro. Glia (1991) 4(3):314-21. doi:10.1002/glia.440040309.
111. Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature (2002) 416(6881):636-40. doi:10.1038/416636a.
112. Yiu G, He Z. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci (2006) 7(8):617-27. doi:10.1038/nrn1956.
113. Zhu X, Bergles DE, Nishiyama A. NG2 cells generate both oligodendrocytes and grey matter astrocytes. Development (2008) 135(1):145-57. doi:10.1242/dev.004895.
114. Fidler PS, Schuette K, Asher RA, Dobbertim A, Thornton SR, Calle-Pantino Y, et al. Comparing astrocytic cell lines that are inhibitory or permissive for axon growth: the major axon-inhibitory proteoglycan is NG2. J Neurosci (1999) 19(20):8778-88.
115. Sobel RA. Ephrin A receptors and ligands in lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol (2005) 15(1):35-45. doi:10.1111/j.1750-3639.2005.tb00098.x.
116. Wahl S, Barth H, Ciossek T, Aktories K, Mueller BK. Ephrin-A5 induces collapse of growth cones by activating Rho and Rho kinase. J Cell Biol (2000) 149(2):263-70. doi:10.1083/jcb.149.2.263.
117. Satoh J, Tabunoki H, Yamamura T, Arima K, Konno H. TROY and LINGO-1 expression in astrocytes and macrophages/microglia in multiple sclerosis lesions. Neuropathol Appl Neurobiol (2007) 33(1):99-107. doi:10.1111/j.1365-2990.2006.00787.x.
118. Fujita Y, Takashima R, Endo S, Takai T, Yamashita T. The p75 receptor mediates axon growth inhibition through an association with PIR-B. Cell Death Dis (2011) 2:e198. doi:10.1038/cddis.2011.85.
119. Thomas R, Favell K, Morante-Redolat J, Pool M, Kent C, Wright M, et al. LGl1 is a Nogo receptor 1 ligand that antagonizes myelin-based growth inhibition. J Neurosci (2010) 30(19):6607-12. doi:10.1523/JNEUROSCI. 5147-09.2010.
120. Zhang L, Zheng S, Wu H, Wu Y, Liu S, Fan M, et al. Identification of BLyS (B lymphocyte stimulator) a non-myelin-associated protein as a functional ligand for Nogo-66 receptor. J Neurosci (2009) 29(19):6348-52. doi:10.1523/JNEUROSCI. 5040-08.2009.
121. Lee H, Raiker SJ, Venkatesh K, Geary R, Robak LA, Zhang Y, et al. Synaptic function for the Nogo-66 receptor NgR1: regulation of dendritic spine morphology and activity-dependent synaptic strength. J Neurosci (2008) 28(11):2753-65. doi:10.1523/JNEUROSCI. 5586-07.2008.
122. Borrie SC, Baeumer BE, Bandtlow CE. The Nogo-66 receptor family in the intact and disease CNS. Cell Tissue Res (2012) 349(1):105-17. doi:10.1007/s00441-012-1332-9.
123. Schwab ME, Strittmatter SM. Nogo limits neural plasticity and recovery from injury. Curr Opin Neurobiol (2014) 27:53-60. doi:10.1016/j.conb.2014.02.011.
124. Broholm H, Andersen B, Wanscher B, Frederiksen JL, Rubin I, Pakkenberg B, et al. Nitric oxide synthase expression and enzymatic activity in multiple sclerosis. Acta Neurol Scand (2004) 109(4):261-9. doi:10.1111/j.1600-0404.2004.00207.x.
125. De Keyser J, Zeinstra E, Wilczak N. Astrcoytic beta-2 adrenergic receptors and multiple sclerosis. Neurobiol Dis (2004) 15(2):331-9. doi:10.1016/j.nbd.2003.10.012.
126. Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, et al. Mitochondrial changes within axons in multiple sclerosis. Brain (2009) 132(Pt 5):1161-74. doi:10.1093/brain/awp046.
127. Gunter TE, Yule DI, Gunter KK, Eliseev RA, Salter JD. Calcium and mitochondria. FEBSS Lett (2004) 567(1):96-102. doi:10.1016/j.febslet.2004.03.071.
128. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci (2005) 233(1-2):3-13. doi:10.1016/j.jns.2005.03.031.
129. De Keyser J, Wilczak N, Leta R, Streetland C. Astrocytes in multiple sclerosis lack beta-2 adrenergic recpetors. Neurology (1999) 53(8):1628-33. doi:10.1212/WNL.53.8.1628.
130. Patel TB, Clark JB. Synthesis of N-Acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J (1979) 184(3):539-46.
131. Brookes N. Regualtion of the glutamine content of astrocytes by cAMP and hydrocortisone: effect of pH. Neurosci Lett (1992) 147(2):139-42. doi:10.1016/0304-3940(92)90579-V.
132. Sloane JA, Hollander W, Rosene DL, Moss MB, Kemper T, Abraham CR. Astrcoytic hypertrophy and altered GFAP degradation with age in subcortical white matter of the rhesus monkey. Brain Res (2000) 862(1-2):1-10. doi:10.1016/S0006-8993(00)02059-X.
133. Porchet R, Probst A, Bouras C, Drabevora E, Draber P, Riederer BM. Analysis of glial fibrillary protein protein in the human enthorinal cortex during aging and Alzheimer's disease. Proteomics (2003) 3(8):1476-85. doi:10.1002/pmic.200300456.
134. Salminen A, Ojala J, Kaarmiranta K, Haapasalo A, Hiltunen M, Soininen H. Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur J Neurosci (2011) 34(1):3-11. doi:10.1111/j.1460-9568.2011.07738.x.
135. de Sampaio e Spohr TC, Martinez R, da Silva EF, Neto VM, Gomes FC. Neuro-glia interactions effects on GFAP gene: a novel role for transforming growth factor-beta 1. Eur J Neurosci (2002) 16(11):2059-69. doi:10.1046/j.1460-9568.2002.02283.x.
136. Landfield PW, Braun LD, Pitler TA, Lindsey JD, Lynch G. Hippocampal aging in rats: a morphometric study of multiple variables in semithin sections. Neurobiol Aging (1981) 2(4):265-75. doi:10.1016/0197-4580(81)90034-8.
137. Li C, Zhao R, Gao K, Wei Z, Yin MY, Lau LT, et al. Astrocytes implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2011) 8(1):67-80. doi:10.2174/156720511794604543.
138. Simard M, Arcuino G, Takano T, Liu QS, Nedergaard M. Signaling at the gliovascualr interface. J Neurosci (2003) 23(27):9254-62.
139. Pedrazzi M, Patrone M, Passalacqua M, Ranzato E, Colamassaro D, Sparatore B, et al. Selective proinflammatory activation of astrcoytes by high-mobility group box 1 protein signaling. J Immunol (2007) 179(12):8525-32. doi:10.4049/jimmunol.179.12.8525.
140. Sun Y, Chen H, Dai J, Zou H, Gao M, Wu H, et al. HMGB1 expression patterns during the progression of experimental autoimmune encephalomyelitis. J Neuroimmunol (2015) 280:29-35. doi:10.1016/j.jneuroim.2015.02.005.